New drug cocktail aims to boost stem cell harvest for rare immune disease
NCT ID NCT03055247
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This phase II trial tests whether a combination of ibuprofen, G-CSF, and plerixafor can safely and effectively mobilize stem cells from the bone marrow into the blood in people with X-linked chronic granulomatous disease (X-CGD). Only 3 adults aged 18-45 are being enrolled. The goal is to collect enough stem cells for future gene therapy, which could help control the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Ibuprofen, G-CSF, and Plerixafor
- What this could lead to
- If successful, this could improve stem cell collection for gene therapy in X-CGD, potentially enabling a one-time treatment that reduces infections.
- What could go wrong
- This is a very small early-phase trial with only 3 participants, so results may not apply broadly. The drug combination may cause side effects like bone pain or allergic reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC GRANULOMATOUS DISEASE X-LINKED (X-CGD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ospedale Pediatrico Bambino Gesù
RECRUITINGRome, Lazio, 00165, Italy
-
Ospedale San Raffaele
RECRUITINGMilan, Lombardy, 20132, Italy